Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection  by Abt, Michael C. et al.
Article
Innate Immune Defenses Mediated by Two ILC
Subsets Are Critical for Protection against Acute
Clostridium difficile InfectionGraphical AbstractHighlightsd Recovery from acute C. difficile infection is independent of
adaptive immunity
d Lack of innate lymphoid cells leads to mortality following
C. difficile infection
d Transfer of ILCs into susceptible hosts restores protection
against C. difficile
d Type-1 ILCs mediate IFN-g-dependent protection against
C. difficileAbt et al., 2015, Cell Host & Microbe 18, 27–37
July 8, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.chom.2015.06.011Authors
Michael C. Abt, Brittany B. Lewis,
Silvia Caballero, ..., Lilan Ling,
Ingrid Leiner, Eric G. Pamer
Correspondence
abtm@mskcc.org (M.C.A.),
pamere@mskcc.org (E.G.P.)
In Brief
C. difficile pathogenicity is determined by
strain virulence, interactions with
commensal bacteria, and the host’s
inflammatory response to intestinal
epithelial damage. Abt et al. demonstrate
that type-1 and type-3 innate lymphoid
cells function in concert and coordinate
early host responses to provide initial
resistance against C. difficile infection.Accession Numbers991836
Cell Host & Microbe
ArticleInnate Immune Defenses Mediated by Two
ILC Subsets Are Critical for Protection
against Acute Clostridium difficile Infection
Michael C. Abt,1,* Brittany B. Lewis,1 Silvia Caballero,1 Huizhong Xiong,1 Rebecca A. Carter,1 Boze Susac,1 Lilan Ling,2
Ingrid Leiner,1 and Eric G. Pamer1,2,3,*
1Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2Lucille Castori Center for Microbes Inflammation and Cancer, Molecular Microbiology Core Facility, Memorial Sloan Kettering Cancer
Center, New York, NY 10065, USA
3Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
*Correspondence: abtm@mskcc.org (M.C.A.), pamere@mskcc.org (E.G.P.)
http://dx.doi.org/10.1016/j.chom.2015.06.011SUMMARY
Infection with the opportunistic enteric pathogen
Clostridium difficile is an increasingly common
clinical complication that follows antibiotic treat-
ment-induced gut microbiota perturbation. Innate
lymphoid cells (ILCs) are early responders to enteric
pathogens; however, their role during C. difficile
infection is undefined. To identify immune pathways
that mediate recovery from C. difficile infection, we
challenged C57BL/6, Rag1/ (which lack T and B
cells), and Rag2/ Il2rg/ (Raggc/) mice (which
additionally lack ILCs) with C. difficile. In contrast to
Rag1/ mice, ILC-deficient Raggc/ mice rapidly
succumbed to infection. Rag1/ but not Raggc/
mice upregulate expression of ILC1- or ILC3-associ-
ated proteins following C. difficile infection. Protec-
tion against infection was restored by transferring
ILCs into Raggc/ mice. While ILC3s made a minor
contribution to resistance, loss of IFN-g or T-bet-
expressing ILC1s inRag1/mice increased suscep-
tibility to C. difficile. These data demonstrate a crit-
ical role for ILC1s in defense against C. difficile.
INTRODUCTION
Clostridium difficile is the leading cause of hospital-acquired
gastrointestinal infections, with C. difficile-related deaths having
increased by 400% over the past decade (Hunt and Ballard,
2013; Lucado et al., 2012). C. difficile establishes infection
following disruption of the indigenous microbiota, usually the
result of preceding antibiotic treatment (Rupnik et al., 2009; Vis-
wanathan et al., 2010). Antibiotic treatments for C. difficile infec-
tion (CDI) are often ineffective (Huang et al., 2009; Johnson,
2009; Pepin et al., 2005), and complications associated with
recurrent CDI in hospitalized patients interfere with medical ther-
apies until infection is brought under control (Chopra et al., 2010;
Dubberke et al., 2010).
While progress has been made in identifying specific
commensal bacterial species that can preventC. difficile replica-Ction (Buffie et al., 2015; Lawley et al., 2012; Seekatz et al., 2014;
Tvede et al., 2015), the role of the host’s natural defenses in
limiting disease severity is not well understood. In humans, circu-
lating antibodies specific forC. difficile toxin A correlate with less
severe infections and lower relapse rates, suggesting that hu-
moral immunity contributes to defense in chronic and recurrent
infections (Kyne et al., 2000, 2001). A recently developed mouse
model has provided insights into innate immune defenses
against CDI (Chen et al., 2008). Inoculation of antibiotic-pre-
treated mice with C. difficile spores results in acute colitis, with
growth of vegetative, oxygen-intolerant, and toxin-secreting
C. difficile bacteria (Chen et al., 2008). The tcdA and tcdB genes
of C. difficile, which encode toxin A and toxin B, respectively,
glycosylate and inactivate Rho GTPases of colonic epithelial
cells, leading to loss of intestinal barrier integrity and infiltration
of inflammatory cells into the colonic lamina propria (Just et al.,
1995; Lyras et al., 2009; Voth and Ballard, 2005). In mice, the
acute phase of CDI progresses for 2–5 days following spore
inoculation and is followed by recovery, with weight gain and res-
olution of diarrhea despite continued growth of C. difficile bacte-
ria and toxin A and B production (Buffie et al., 2012; Lawley et al.,
2009). The hostmechanisms underlying recovery from acute CDI
remain incompletely defined; however, innate immune signaling
pathways have been implicated in early host defense. Loss of
specific innate immune defense components, such as MyD88,
ASC, NOD1, or infiltrating neutrophils, increases mortality in
mice during acute CDI (Hasegawa et al., 2011, 2012; Jarchum
et al., 2012; Lawley et al., 2009).
Innate lymphoid cells (ILCs) reside in the intestine and
contribute to restoration of intestinal integrity following infection
(Artis and Spits, 2015). Type-1 ILCs (ILC1s) produce IFN-g and
TNF-a and limit Toxoplasma gondii replication in the intestine
(Bernink et al., 2013; Fuchs et al., 2013; Klose et al., 2014).
ILC2s provide resistance against helminth infections via IL-5
and IL-13 secretion, while ILC3s contribute to defense against
invasive bacteria such as Citrobacter rodentium via production
of IL-22 (Artis and Spits, 2015). Further, Nfil3/ mice, which
have a developmental defect in ILC maturation resulting in
absence of all ILC subsets, are more susceptible to CDI (Geiger
et al., 2014). However, the contributions of different ILC subsets
to resolution of the acute phase of CDI remain undefined.
In this report we examine the role of ILCs in the innate immune
response to CDI. We find that recovery from the acute phase ofell Host & Microbe 18, 27–37, July 8, 2015 ª2015 Elsevier Inc. 27
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Figure 1. Absence of Innate Lymphoid Cells
Leads to Increased Susceptibility to
C. difficile
(A) C57BL/6, Rag1/, and Raggc/ mice were
inoculated with 200 spores of C. difficile (VPI
10463 strain) and assessed for survival following
infection. Survival curve is a combination of five
independent experiments (C57BL/6, n = 23;
Rag1/, n = 12; Raggc/, n = 8).
(B and C) At day 2 post-infection, (B) C. difficile
burden and (C) toxin levels were measured from
the cecal content.
(D) Representative H&E-stained cecal sections
from antibiotic-treated, uninfected, and day 2-in-
fected C57BL/6, Rag1/, and Raggc/ mice.
Scale bar = 100 mm.
(E) Pathology score of histological tissue sections
basedoncellular infiltration/edema (host response),
and epithelial layer degeneration (n = 9–11). *p <
0.05, **p < 0.01. ns = not significant. Data shownare
mean ± SEM. See also Figures S1 and S2.CDI does not depend on the adaptive immune system, but that
the loss of ILCs markedly increases acute phase mortality.
Adoptive transfer of CD90+ CD127+ ILCs into highly susceptible,
ILC-deficient mice enabled mice to recover from CDI. While se-
lective loss of ILC3s or IL-22 modestly reduced resistance to
acute CDI, loss of T-bet-expressing ILC1s or the ILC1-derived
effector cytokine IFN-g markedly increased morbidity and mor-
tality. Our results reveal a cooperative role for two ILC subsets
in host defense against acute CDI, with ILC3s making a minor
contribution to the more significant impact of ILC1s in the recov-
ery phase.
RESULTS
Absence of ILCs Increases Susceptibility to Acute CDI
ILCs reside within the intestinal wall, including the epithelial
layer and the underlying lamina propria, and contribute to
the maintenance of tissue integrity following infection-medi-
ated damage (Artis and Spits, 2015; Diefenbach, 2013). The
role of ILCs in the early host response to CDI, however, is
undefined. To address this question, we used a murine model
of CDI. C57BL/6, Rag1/, and Rag2/ common gamma
chain double-knockout (Raggc/) mice were cohoused for
3 weeks to equilibrate the intestinal microbiota (Ubeda
et al., 2012). Mice were then treated with neomycin
(0.25 g/l) and vancomycin (0.25 g/l) in the drinking water for
3 days, followed by a single intraperitoneal (i.p.) injection of
clindamycin (Buffie et al., 2012; Lewis et al., 2015; Rupnik
et al., 2009; Wren et al., 2005) (Figure S1A). Antibiotic-treated
mice were orally challenged with a low dose of C. difficile
spores (200 spores), an inoculum that likely approximates28 Cell Host & Microbe 18, 27–37, July 8, 2015 ª2015 Elsevier Inc.both the route and dose acquired by
humans in a healthcare setting. We
have used the VPI 10463 C. difficile
strain, which produces high amounts
of toxin A and B and causes intestinal
epithelial damage, leading to therecruitment of infiltrating inflammatory immune cells into the
intestine (Chen et al., 2008).
C57BL/6 and Rag1/ mice had similar survival (Figure 1A),
weight loss (Figure S1B), C. difficile burden (Figure S1C),
C. difficile toxin levels (Figure S1D), and tissue damage in the
large intestine (Figures S1D and S1E) following infection, indi-
cating that the innate immune response is capable of mediating
host recovery from acute CDI. In contrast, Raggc/mice were
susceptible to acute CDI, did not progress to the recovery phase,
and succumbed within 5 days of spore inoculation (Figure 1A).
Increased mortality in Raggc/mice was not the result of an
elevated intestinal C. difficile burden (Figure 1B) or increased
toxin levels (Figure 1C) following infection. Deep-sequencing of
16S rRNA isolated from the fecal pellets of cohoused Raggc/
and C57BL/6 mice demonstrated intestinal microbiota equilibra-
tion prior to infection (Figures S2A–S2C), suggesting that an
aberrant intestinal microbiota in Raggc/ mice did not prevent
recovery from acute CDI. Histological examination of the cecum
2 days following infection revealed that C57BL/6, Rag1/, and
Raggc/ mice had similar damage to the epithelial layer but
that Raggc/mice had decreased edema and fewer infiltrating
immune cells (Figures 1F and 1G). At day 2 post-infection, all
three groups had detectable levels of albumin in the cecal con-
tent (Figure S2D), indicating intestinal epithelial damage, but
only Raggc/ mice had incidences of LPS in the serum (Fig-
ure S2E). Consistent with a compromised intestinal barrier,
blooms of bacteria were detected by fluorescence in situ hybrid-
ization within the large intestinal crypts and the submucosa of
Raggc/ mice at day 2 post-infection (Figure S2F). These
data suggest that common gamma chain-dependent ILCs are
essential for recovery from acute CDI.
Rag1–/– but Not Raggc–/– Mice Upregulate Expression of
ILC1- or ILC3-Associated Proteins Following CDI
Reduced recovery of Raggc/ mice during CDI suggests that
ILCs enable the host to re-establish a homeostatic state despite
continued infection with toxin-producing bacteria. To begin to
dissect the relative contributions of ILC1s, ILC2s, and ILC3s
following CDI, C57BL/6, Rag1/ and Raggc/ mice were as-
sessed for expression of ILC1-, ILC2-, and ILC3-associated
genes in the colon. Two days following spore inoculation,
C57BL/6 and Rag1/ mice had increased expression of Ifng
(Figure 2A) and Il22 and Il17a (Figure 2B) mRNA in the colon
compared to uninfected control mice, while infected Raggc/
mice failed to upregulate transcription of these genes. Further,
Nos2 (Figure 2A) and Reg3g (Figure 2B), IFN-g- and IL-22-induc-
ible genes, respectively, were significantly increased in C57BL/6
and Rag1/ mice compared to Raggc/ mice following infec-
tion, suggesting an impairment in the ILC1 and ILC3 response
axis. ILC2-associated effector molecules Il5, Il13, and Areg
were not differentially expressed between day 2-infected
C57BL/6, Rag1/, and Raggc/ mice (Figure 2C), suggesting
that ILC2s are not major contributors to recovery from acute
CDI. Supernatants from cecal tissue explants confirmed signifi-
cantly decreased production of IFN-g (Figure 2D) and IL-22 (Fig-
ure 2E) in day 2-infected Raggc/ mice compared to day 2-in-
fected C57BL/6 and Rag1/ mice on the protein level. ILC1s
can be stimulated by IL-12 (composed of p35 and p40 subunits)
to produce IFN-g, while ILC3s are activated by IL-23 (composed
of p19 and p40 subunits) and/or IL-1b to produce IL-22 (Artis and
Spits, 2015). Induction of Il1b and p35 mRNA and constitutive
expression of p40 and p19 mRNA in the colon was comparable
in day 2-infected C57BL/6, Rag1/, and Raggc/ mice (Fig-
ure 2F), suggesting that the upstream machinery for ILC activa-
tion remained intact in Raggc/mice following infection. These
data demonstrate that induction of IFN-g and IL-22-mediated
effector mechanisms following CDI is absent in susceptible,
ILC-deficient Raggc/mice.
ILCs Are the Predominant Source of IL-22 and IFN-g
Following CDI
To identify the early cellular source of IFN-g and IL-22 following
CDI, Rag1/ and Raggc/mice were sacrificed at day 2 post-
infection, and cells isolated from the large intestine were as-
sessed for cytokine production by flow cytometric analysis. In
the absence of any ex vivo stimulation, IL-22+, IL-22+/IFN-g+,
and IFN-g+ cells were recovered from day 2-infected Rag1/
mice (Figure 3A). These IFN-g- and IL-22-expressing cells pre-
dominantly expressed CD90 and CD127 (Figure 3B), canonical
surface markers for ILCs (Sonnenberg et al., 2013), and were
significantly increased compared to infected Raggc/mice
and uninfected Rag1/ mice (Figure 3C). A similar induction of
IFN-g+ and IL-22+ ILCs was observed in the mesenteric lymph
nodes (mLN) of day 2-infected Rag1/mice compared to unin-
fected control mice (Figures S3A–S3C). To assess whether ILCs
are the predominant early source of IFN-g and IL-22 in fully
immunocompetent hosts, CD4+ T cells and ILCs from the mLN
of uninfected or day 2-infected C57BL/6 mice were assessed
for cytokine production (Figure S3D). While there was no induc-
tion of cytokine-producing CD4+ T cells at day 2 post-infection
(Figure S3E), there was a significant increase in IL-22+ andCIFN-g+ ILCs in infected C57BL/6 mice compared to uninfected
control mice (Figure S3F). Further analysis of these cytokine-pro-
ducing ILCs revealed that the majority of IL-22-producing cells
were CD4+ LTi-like cells while the majority of IFN-g-producing
cells were NK1.1+ NKp46+ ILC1s (Figure S3G). Combined, these
data demonstrate that IL-22- and IFN-g-producing ILCs are
induced in the large intestine and associated lymphoid tissue
in both C57BL/6 and Rag1/mice following CDI. Further, these
CD90+ CD127+ ILCs are the major early source of IL-22 and
IFN-g following CDI and are absent in Raggc/ mice.
Adoptive Transfer of ILCs into Raggc–/– Mice Restores
Host Defense against C. difficile
Raggc/ mice lack IL-22- and IFN-g-producing ILCs following
inoculation with C. difficile and are unable to recover from acute
infection. To assess if this cell population is sufficient to re-estab-
lish resistance in Raggc/ mice against acute CDI, CD90+
CD127+ ILCs were sorted from the spleen, lymph nodes, and in-
testines of naive Rag1/ mice and adoptively transferred into
recipient Raggc/ mice. The sort-purified population of
CD90+ CD127+ ILCs consisted of T-bet-expressing ILC1s,
GATA-3-expressing ILC2s, and RORgt-expressing ILC3s (Fig-
ure S4A) and, as previously reported by (Klose et al., 2013),
3 weeks following adoptive transfer into recipient Raggc/
mice, donor CD90+ CD127+ ILCs were present in the large intes-
tine (Figure 4A), spleen (Figure S4B), and small intestine (Fig-
ure S4C). Transcriptional profiling of donor ILCs in Raggc/
ILC recipients confirmed the presence of all three ILC subsets
as well as Eomes+ T-bet+ ‘‘classical’’ NK cells (Gordon et al.,
2012) (Figure 4A and Figure S4). Raggc/ ILC recipient mice
received a second transfusion of CD90+ CD127+ ILCs and
were challenged with C. difficile spores along with Rag1/
and Raggc/ mice. As shown previously (Figure 1), Raggc/
mice had reduced recovery from acute CDI compared to
Rag1/ mice (Figure 4B), as determined by a morbidity score
consisting of weight loss, body temperature, diarrhea severity,
and lethargy (Warren et al., 2012), and rapidly succumbed to
infection (Figure 4C). In contrast, Raggc/ ILC recipient mice
had reduced morbidity and mortality following infection
compared to Raggc/ mice not receiving ILCs (Figures 4B
and 4C), demonstrating the capacity of ILCs to promote recovery
from acute CDI.
Selective Loss of ILC3s or ILC3 Effector Molecules
Reveals Their Limited Role in Recovery Following
Acute CDI
Adoptive transfer of CD90+ CD127+ ILCs into Raggc/ mice
improved survival following C. difficile challenge, demonstrating
the contribution of these cells to the re-establishment of
gut homeostasis following acute phase infection. However,
the relative contribution of distinct ILC subsets to host defense
against acute C. difficile remained unresolved. RORgt-express-
ing ILC3s provide protection against the attaching and
effacing bacterial pathogen Citrobacter rodentium via IL-22
production (Satoh-Takayama et al., 2008; Sonnenberg et al.,
2011). IL-22 is also produced by ILCs following CDI (Figures 2
and 3) and thus could contribute to recovery from acute CDI.
To address the relative contribution of ILC3s in host defense
against CDI, Rorc/ mice and heterozygous littermate controlell Host & Microbe 18, 27–37, July 8, 2015 ª2015 Elsevier Inc. 29
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Figure 2. C57BL/6 and Rag1–/– but Not Raggc–/– Mice Upregulate Expression of ILC1- or ILC3-Associated Proteins Following C. difficile
Infection
(A–C) Fold induction of (A) ILC1-, (B) ILC3-, and (C) ILC2-associated effector molecules in the colon at day 2 post-infection relative to uninfected C57BL/6 (B6
Uninf) mice and normalized to Hprt.
(D and E) IFN-g (D) and IL-22 (E) protein in the supernatant of cecal tissue explants.
(F) Fold induction of genes upstream of ILC1 and ILC3 activation (n = 7–13). *p < 0.05, **p < 0.01. Data shown are mean ± SEM. b.d., below detection.mice were challenged with C. difficile. Surprisingly, no statisti-
cally significant difference in weight loss (Figure 5A) or survival
(Figure 5B) was detected between the Rorc/ and heterozy-30 Cell Host & Microbe 18, 27–37, July 8, 2015 ª2015 Elsevier Inc.gous littermate control mice. Rorc/ mice lack all lymphoid
structures and have an altered intestinal T cell repertoire (Eberl
and Littman, 2004; Eberl et al., 2004), complicating interpretation
0 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
0 103 104 105
0
102
103
104
105
0 103 104 105
0
102
103
104
105
B
IFN-γ
IL
-2
2
Uninfected
CD127
C
D
90
A
Rag1-/- D2 Ragγc-/- D2
22-LI
+
s
CLI
01x(
2 )
γ-
NFI
+
s
CLI
01x(
3 )
Uninf
Rag1-/- Ragγc-/-Rag1-/-
Day 2
0
2.5
5
78.1 
± 7.9
0.7±
0.2
4.0± 
0.6
0.1± 0.1
100 
± 0.0
87.5 
± 6.0
1.4± 
0.5
0.2± 0.10.3± 0.1 0.0± 0.0 0.03± 0.00.13± 0.0
IFN-γ+ IFN-γ+ IL-22+ IL-22+ 
0
1.5
3
γ-
NFI
+
22-LI
+
s
CLI
01x(
2 ) * *
0
2.5
5 * **
Uninf
Rag1-/- Ragγc-/-Rag1-/-
Day 2 Uninf
Rag1-/- Ragγc-/-Rag1-/-
Day 2
C
ns ns
Figure 3. IL-22 and IFN-g Expressing ILCs
Are Induced in the Large Intestine Following
C. difficile Infection
(A–C) Cells isolated from the large intestine intra-
epithelial compartment of uninfected Rag1/,
day 2-infected Rag1/, or day 2-infected
Raggc/ mice were incubated in media in the
presence of brefeldin A and assessed for IL-22
and IFN-g production. (A) Frequency of IL-22+,
IFN-g+, and IL-22+/ IFN-g+ cells. FACS plots gated
on live CD45+ Gr-1neg cells. (B) Expression of
CD90 and CD127 on cytokine-positive cells from
day 2-infected Rag1/ mice. (C) Number of IL-
22+, IFN-g+, and IL-22+/IFN-g+ ILCs. Data are
representative of three independent experiments
(n = 4–5). *p < 0.05, **p < 0.01. Data shown are
mean ± SEM. See also Figure S3.of experimental results with these mice. To address this issue,
we used Il22/mice and assessed the host response following
acute CDI. Il22/ mice had significant albeit transiently
increased weight loss between days 2 and 5 of infection
compared to control C57BL/6 mice (Figure 5C), but no statisti-
cally significant difference in rate of survival (Figure 5D). At day
3 post-infection, Il22/ and C57BL/6 mice had equivalent
C. difficile burdens (Figure 5E) and toxin levels (Figure 5F) in
the cecum, indicating similar establishment of CDI. Further, while
expression of IL-22-dependent Reg3g was significantly
decreased in Il22/ mice compared to C57BL/6 mice, there
was no difference in the induction of Ifng or IFN-g-inducible
Nos2 at day 3 post-infection (Figure 5G). These data suggest
that in the absence of ILC3-mediated IL-22 production, the
ILC1 response remains intact.
Our observations demonstrating a modest impact of IL-22
deficiency on recovery from acute CDI contrast with those
recently reported (Hasegawa et al., 2014). To reconcile our
apparently disparate observations, we pretreated Il22/ and
C57BL/6 mice with a cocktail of six broad-spectrum antibiotics
and then orally challenged mice with a vegetative culture of
C. difficile (instead of spores) as described (Hasegawa et al.,
2012, 2014) (Figure S5A). This inoculum consisted of 5 3 107–
1 3 108 CFUs of the vegetative form as well as 600 sporesCell Host & Microbe 18,per mouse (Figure S5B). Under these
conditions, infected Il22/ mice had
higher disease severity (Figure S5C) and
significantly increased mortality com-
pared to infected C57BL/6 mice (Fig-
ure S5D). These results indicate that the
relative contributions of innate immune
cells to infection by the same pathogen
can differ, depending on the context in
which the host is exposed to the path-
ogen. Our results, we believe, uncover
innate immune mechanisms that are
involved in early defense against CDI ac-
quired by ingestion of spores, the most
likely mechanism of transmission in a
hospital setting, while the results of Hase-
gawa et al. may reveal mechanisms ofimmune defense during more severe and perhaps later stages
of C. difficile-induced sepsis.
It is possible that ILC3s contribute to resolution of acute CDI in
an IL-22-independent manner. IL-17a is another effector cyto-
kine produced by ILC3s that is upregulated following acute
CDI (Figure 2B) (Sadighi Akha et al., 2013) and has been impli-
cated in host defense against bacterial and fungal pathogens
(Gladiator et al., 2013; Ye et al., 2001). To assess the potential
role for IL-17a in host defense against C. difficile, we adminis-
tered anti-IL-17a neutralizing or isotype control antibodies to
Rag1/mice followed by oral challenge with C. difficile spores.
Rag1/mice receiving IL-17a blockade did not have enhanced
weight loss (Figure 5H) or mortality (Figure 5I) following infection
compared to isotype-treated Rag1/ mice. Anti-IL-17a treat-
ment did increase susceptibility to pulmonary Klebsiella pneu-
moniae infection, a pathogen where IL-17 is known to be critical
for host defense (Ye et al., 2001), demonstrating the efficacy of
the IL-17 blockade therapy (Figures S5E–S5G). To further assess
the contribution of ILC-derived IL-17a, Rag1/ mice were
crossed with Il17a/ mice to generate Rag1/ Il17a/ mice
(Rag.Il17 dKO). Rag.Il17 dKO mice infected with C. difficile
spores did not exhibit increased mortality following infection
compared to Rag1/ mice (Figure 5J). Combined, these data
suggest that ILC3-derived IL-17a does not significantly27–37, July 8, 2015 ª2015 Elsevier Inc. 31
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Figure 4. Adoptive Transfer of ILCs into
Raggc–/– Mice Restores Host Defense
Following C. difficile Infection
(A–C) Reconstitution of ILC compartment (A) in the
large intestine lamina propria of recipient
Raggc/ mice 3 weeks after ILC transfer.
Rag1/, Raggc/, and Raggc/ + ILCs mice
were infected with C. difficile and were assessed
for (B) disease severity and (C) survival following
infection. A combination of five independent ex-
periments is shown (n = 15–18). *p < 0.05, **p <
0.01. Data shown are mean ± SEM. See also
Figure S4.contribute to host defense against acute CDI. Our finding that the
loss of ILC3-associated effector molecules only modestly im-
pacts recovery from acute CDI suggests that other ILC subsets
are important contributors to host defense against CDI.
T-bet-Expressing ILC1s Are Critical for Host Defense
against C. difficile
Ablation of ILC3-mediated effector molecules did not recapitu-
late the phenotype observed in Raggc/ mice following CDI,
and the ILC1 response remained intact in C. difficile-infected
Il22/ mice, suggesting that an ILC1-dependent mechanism
could be important in mediating protection. ILC1 maturation is
dependent on expression of the transcription factor T-bet (Klose
et al., 2014). C57BL/6 andRag1/mice do not differ in their abil-
ity to recover from acute CDI (Figure S1) (Hasegawa et al., 2014);
therefore, to assess ILC1 contributions to defense against acute
CDI,Rag1/micewere crossedwith Tbx21/mice to generate
Rag1/ Tbx21/ mice (Rag.Tbet dKO). Rag.Tbet dKO mice32 Cell Host & Microbe 18, 27–37, July 8, 2015 ª2015 Elsevier Inc.may develop spontaneous colitis de-
pending on the composition of the host
microbiota (Garrett et al., 2007; Powell
et al., 2012); however, the Rag.Tbet
dKO mice generated for these studies
did not exhibit any overt signs of colitis
(data not shown). Eight-week-old naive
Rag1/ and Rag.Tbet dKO mice had
similar numbers of ILC2s (Figure S6A),
ILC3s (Figure S6A), and Eomes+ NK1.1+
‘‘classical’’ NK cells (Figure S6B) while
having significantly fewer Eomesneg
NK1.1+ ‘‘ILC1s’’ (Figure S6B), which pre-
dominantly express T-bet (Figure S6C),
in the large intestine lamina propria (Fig-
ure S6D), mLN (Figure S6E), spleen (Fig-
ure S6F), and liver (Figure S6G). Following
CDI, disease severity (Figure 6A) and
mortality (Figure 6B) were markedly
increased in Rag.Tbet dKO mice
compared to littermate Rag1/ TbetHET
mice. The greater than 50% mortality
rate observed in Rag.Tbet dKO mice
was similar to that observed in Raggc/
mice (Figure 1A), indicating that T-bet-ex-
pressing ILC1smake amajor contributionto recovery from acute CDI. While induction of Il22 and IL-22
dependent Reg3g genes was comparable between Rag.Tbet
dKO and Rag1/ TbetHET mice at day 2 post-CDI, Ifng expres-
sion was significantly decreased in Rag.Tbet dKO mice, indica-
tive of a defective ILC1 response in these mice (Figure 6C). To
assess whether ILC1s act through IFN-g to protect the host
against C. difficile, Rag1/ Ifng/ double-knockout mice (Ra-
g.Ifng dKO) were generated and challenged with C. difficile
spores along with cohoused Rag1/ mice. Similar to Rag.Tbet
dKO mice, Rag.Ifng dKO mice had significantly higher disease
scores than infected Rag1/ mice (Figure 6D) and rapidly suc-
cumbed to infection (Figure 6E). Our results demonstrate the crit-
ical role of T-bet+, IFN-g expressing ILC1s in recovery from acute
CDI. Lastly, we crossed Rag1/ mice with Il22/ mice to
generate Rag1/ Il22/ mice (Rag.Il22 dKO) and used these
mice in combination with IFN-g blockade to assess the additive
impact of these ILC-derived cytokines. Similar to Il22/ mice
(Figures 5C and 5D), Rag.Il22 dKO mice exhibited an
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Figure 5. Selective Loss of ILC3s or ILC3 Effector Molecules Reveals Their Limited Role in Recovery Following Acute C. difficile Infection
(A and B) Weight loss (A) and survival (B) of RorcHET or Rorc/ mice following CDI. A combination of three independent experiments is shown (n = 10–11).
(C–G) C57BL/6 and Il22/mice were infected withC. difficile spores and assessed for (C) weight loss and (D) survival. Weight loss curve is representative of four
independent experiments. Survival curve is a combination of four experiments (n = 21–22). C. difficile burden (E) and toxin levels in the cecal content (F) at day 3
post-infection are shown. (G) Fold induction is shown of Reg3g, Ifng, and Nos2 in the colon of day 3-infected C57BL/6 and Il22/ mice relative to uninfected
C57BL/6 mice and normalized to Hprt (n = 7–8).
(H and I) Weight loss (H) and survival (I) of Rag1/ or Rag1/ mice treated with anti-IL-17a neutralizing antibody (n = 8).
(J) Survival of Rag1/ or Rag.Il17 dKO mice (n = 7–9). *p < 0.05, **p < 0.01. Data shown are mean ± SEM. See also Figure S5.intermediate phenotype following CDI with a trend toward
increased susceptibility following CDI (Figure 6F). However, Ra-
g.Il22 dKO mice that were also treated with IFN-g blockade
rapidly succumbed to infection (Figure 6F), demonstrating the
cooperative role of ILC1s and ILC3s in host defense against
acute CDI.
DISCUSSION
CDI and associated destruction of the colonic epithelial barrier
result from the failure of microbiota-mediated colonization resis-
tance. Upon in vivo colonization, germination, vegetative growth,
and toxin production by C. difficile, innate immune defenses are
engaged that are essential for host survival. Previous studies
have demonstrated the importance of MyD88- and NOD-medi-
ated signaling and neutrophil recruitment in limiting damage toCthe large intestine and for survival following CDI (Hasegawa
et al., 2011; Jarchum et al., 2012; Lawley et al., 2009). In this
report, we demonstrate that innate immune defenses mediated
by ILCs are activated and contribute to recovery from acute
CDI. Adoptive transfer of ILCs into highly susceptible Raggc/
micemarkedly reducesmortality resulting from acute CDI. These
observations and the finding thatNfil3/mice aremore suscep-
tible toC. difficile andC. rodentium infection despite intact T and
B cell function (Geiger et al., 2014), highlight the importance of
ILCs during CDI. Type-3 ILCs and the production of IL-22 have
been implicated in defense against colonic infection with
C. rodentium (Satoh-Takayama et al., 2008; Sonnenberg et al.,
2011; Zheng et al., 2008). In contrast, our studies demonstrate
that recovery from acute CDI was largely mediated by ILC1s
and IFN-g, with a contribution from ILC3s and IL-22. The distinct
contributions of ILC1 and ILC3 subsets to these two colonicell Host & Microbe 18, 27–37, July 8, 2015 ª2015 Elsevier Inc. 33
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Figure 6. Ablation of ILC1s or ILC1-Associated IFN-g Leads to Increased Susceptibility to C. difficile Infection
(A and B) Disease severity (A) and survival (B) ofRag1/ TbetHET or Rag.Tbet dKOmice following CDI. A combination of three independent experiments is shown
(n = 15–17).
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normalized to Hprt (n = 7).
(D and E) Disease severity (D) and survival (E) of Rag1/ or Rag.Ifng dKO mice following CDI. A combination of four independent experiments is shown
(n = 15–17).
(F) Survival of Rag1/, Rag.Il22 dKO, or Rag.Il22 dKOmice treated with anti-IFN-g neutralizing antibody (n = 4–8). *p < 0.05, **p < 0.01, ***p < 0.001. Data shown
are mean ± SEM. See also Figure S6.bacterial pathogens likely result from distinct pathogenic mech-
anisms, with C. difficile mediating epithelial cell damage by
exotoxin secretion whileC. rodentium directly contacts epithelial
cell membranes (Mundy et al., 2005; Viswanathan et al., 2010).
The outcome of CDI is influenced by the virulence ofC. difficile
strains, the composition of the host’s intestinal microbial com-
munities, and the host’s immune response. Infection of mice
with highly virulent strains of C. difficile in a setting of severe mi-
crobiota dysbiosis, following administration of multiple broad-
spectrum antibiotics, can overwhelm innate immune defenses
and lead to mortality (Buonomo et al., 2013; Chen et al., 2008).
Infection of mice with less virulent C. difficile isolates or following
less severe alteration of the microbiota leads to acute infection,
with diarrhea and weight loss, followed by recovery that is medi-
ated by the innate immune system (Buffie et al., 2012; Jarchum34 Cell Host & Microbe 18, 27–37, July 8, 2015 ª2015 Elsevier Inc.et al., 2012). In this setting, innate immune responses enable
mice to regain weight, resolve diarrhea, and survive long-term,
despite continuing to harbor toxin-producing C. difficile bacilli
in their large intestine. Inflammation is part of the host’s innate
immune response to infection. However, if left unchecked, the
proinflammatory immune response can cause tissue destruction
that is detrimental (Chovatiya and Medzhitov, 2014). In the
context of CDI, it is unclear whether the strong inflammatory
response observed in some patients drives disease severity or
is a result of pathogen-induced damage to the intestinal epithe-
lium. Recovery from acute C. difficile colitis likely requires
engagement of mechanisms that restrict systemic dissemination
of intestinal bacteria and their byproducts, potentially by acti-
vating their uptake and destruction by phagocytic cells in the
lamina propria and by re-establishing the intestinal epithelial
barrier. ILC1s and IFN-g-mediated defenses may contribute to
enhanced clearance of bacteria that enter the lamina propria,
thereby limiting their dissemination to the liver and the blood-
stream. Bacteria that do disseminate can activate ILC3s and
are cleared via IL-22 activation of the complement pathway (Ha-
segawa et al., 2014). This inflammatory response, however, must
be tightly regulated to maintain protective features of the inflam-
matory immune response while limiting tissue pathology.
While our study implicates innate IFN-g production in recov-
ery from acute CDI, it is possible that ILC1s are not the sole
source of this cytokine. For example, classical Eomes-express-
ing NK cells produce IFN-g and, in some settings, neutrophils,
and inflammatory monocytes produce IFN-g (Gordon et al.,
2012; Kraaij et al., 2014; Spees et al., 2014). Further, T-bet-ex-
pressing ILC1s may express or induce additional effector
mechanisms that act in conjunction with IFN-g to elicit host de-
fenses against C. difficile. ILC1s express CD160 (Fuchs et al.,
2013), a ligand that is essential for IFN-g secretion by NK cells
(Tu et al., 2015), and can coproduce TNF-a along with IFN-g
(Klose et al., 2014). Antibody blockade of either CD160 or
TNF-a during CDI results in decreased induction of anti-micro-
bial defense genes, suggesting that these may be additional
ILC1-mediated effector mechanisms that contribute to recov-
ery from acute CDI (McDermott et al., 2015; Sadighi Akha
et al., 2015).
A recent report demonstrated a role for IL-22 in defense
against CDI via activation of the C3 complement pathway. In
the absence of IL-22, strains of Enterobacteriaceae translo-
cated from the intestinal lumen into peripheral organs following
C. difficile-induced damage to the intestinal epithelial barrier
(Hasegawa et al., 2014). In contrast, another study demon-
strated that abrogation of the IL-22 signaling pathway via dele-
tion of IL-23 improved survival of C. difficile-infected mice
(Buonomo et al., 2013). These observations suggest a
context-dependent role for ILC3s and IL-22 in limiting systemic
infection by oxygen-tolerant pathobionts that, if present within
the gut lumen, can translocate into the bloodstream following
toxin-induced damage to the epithelial barrier by C. difficile.
Our results, in combination with these studies, implicate a
cooperative role between ILC1s and ILC3s. ILC1s that are
prominent in intestinal intraepithelial space (Bernink et al.,
2013; Fuchs et al., 2013) may limit C. difficile damage by acti-
vating local defenses at the site of infection, while ILC3s acti-
vate innate immune responses in peripheral organs such as
the liver and lung to clear any translocated pathogenic bacteria.
Indeed, systemic administration of bacterial flagellin can elicit
IL-22 production by ILC3s (Kinnebrew et al., 2012) and can pro-
tect against acute C. difficile mortality (Jarchum et al., 2011).
Thus, similar to the role of CD4+ T helper type 1 cells of the
adaptive immune system, ILC1s produce effector cytokines
that activate the anti-bacterial defense programs of bystander
immune cells at the site of infection. Without the requirement
of antigen specificity and subsequent clonal expansion, ILC1s
can rapidly respond to infection and provide initial host de-
fenses against invasive bacteria. This report identifies the
critical role of ILC1s in host defense against C. difficile and sug-
gests the potential for a cooperative role of ILC1s and ILC3s in
limiting pathology following pathogen-induced damage to the
epithelial barrier.CEXPERIMENTAL PROCEDURES
Mice
C57BL/6,Rag1/,Rorc/ (Rorcgfp/gfp), Tbx21/, and Ifng/mice were pur-
chased from the Jackson Laboratory. Raggc/ mice were purchased from
Taconic Farms. Il22/ mice were provided by R. Flavell (Yale University). All
knockout mouse strains were derived on a C57BL/6 background. Rag.Tbet
dKO, Rag.Ifng dKO, Rag.Il17 dKO, and Rag.Il22 dKO mice were generated
by breeding Rag1/ mice with Tbx21/, Ifng/ Il17a/, or Il22/ mice,
respectively. All mice were bred and maintained under specific pathogen-
free conditions at the Memorial Sloan Kettering Research Animal Resource
Center. Sex- and age-matched controls were used in all experiments accord-
ing to institutional guidelines for animal care. All animal procedures were
approved by the Institutional Animal Care and Use Committee of the Memorial
Sloan Kettering Cancer Center.
Antibiotic Pretreatment, CDI, and Mouse Monitoring
Mice were cohoused for 3 weeks prior to antibiotic treatment and then supple-
mented with neomycin (Sigma) (0.25 g/l) and vancomycin (Novaplus) (0.25 g/l)
in the drinkingwater for 3 days. One day following cessation of antibiotic water,
mice received 200 mg of clindamycin (Sigma) by i.p. injection. Twenty-four
hours later, mice received 200 C. difficile spores (VPI10463 strain ATCC
#43255) via oral gavage. For IL-17a or IFN-g blockade experiments, mice
received 400 mg of anti-mIL-17a antibody (clone 17F3, Bio X Cell), anti-
mIFN-g antibody (clone XMG1.2, Bio X Cell) or mouse IgG1 isotype control
antibody (clone MOPC-21, Bio X Cell) i.p. every other day starting at day 1
of infection. After infection, mice were monitored and scored for disease
severity by four parameters: weight loss (> 95% of initial weight = 0, 95%–
90% initial weight = 1, 90%–80% initial weight = 2, < 80% = 3), surface
body temperature (> 32C = 0, 32C–30C = 1, 30C–28C = 2, < 28C = 3),
diarrhea severity (formed pellets = 0, loose pellets = 0, liquidly discharge =
2, no pellets/caked to fur = 3), morbidity (score of 1 for each symptoms with
max score of 3; ruffled fur, hunched back, lethargy, ocular discharge).
Cell Isolation and Ex Vivo Cytokine Detection
Single-cell suspensions from the mLN, intraepithelial lymphocyte compart-
ment, or lamina propria were cultured in a 96-well plate in complete media
and brefeldin A alone (Golgiplug, eBioscience) for 3 hr at 37C. Following incu-
bation, cells were stained for surface molecules, fixed, and intracellularly
stained for IL-22 (clone 1H8PWSR, eBioscience) and IFN-g (clone XMG1.2,
BD Biosciences). For detailed description of procedures, see Supplemental
Experimental Procedures.
ILC Adoptive Transfer
Donor Rag1/ mice received 3 i.p. injections of 2.5 mg rhIL-7 (eBioscience)/
15 mg anti-IL-7 complex (clone M25, Bio X Cell) every other day to expand
the ILC population (Boyman et al., 2008). Twelve hours following the last in-
jection, the spleen, lymph nodes, small intestine, and large intestine were
processed into single-cell suspensions. Samples were stained with fluores-
cently conjugated antibodies and DAPI and then sorted on a BD Aria on
the basis of DAPIneg CD45+ Gr-1neg F4/80neg CD90+ CD127+ with > 92% pu-
rity obtained. Approximately 2 3 105 sort-purified ILCs were transferred by
retro-orbital injection into Raggc/ mice. Three weeks following transfer,
recipient mice, along with Rag1/ and Raggc/ control mice, received
200 mg of clindamycin by i.p. injection on 2 consecutive days and then
were challenged with 200 C. difficile spores (VPI10463) (Buffie et al., 2012).
Recipient Raggc/ mice received an additional ILC transfer 24 hr following
infection, and all groups were monitored for morbidity and mortality.
Tissue RNA Isolation, cDNA Preparation, and RT-PCR
RNA was isolated from colon tissue using mechanical homogenization and
TRIzol isolation (Invitrogen) according to the manufacturer’s instructions.
cDNA was generated using QuantiTect reverse transcriptase (QIAGEN).
RT-PCR was performed on cDNA using TaqMan primers and probes in com-
bination with TaqMan PCR Master Mix (ABI), and reactions were run on a
RT-PCR system (StepOne Plus, Applied Biosystems). Gene expression is
displayed as fold increase over antibiotic-pre-treated, uninfected control
mice and normalized to Hprt.ell Host & Microbe 18, 27–37, July 8, 2015 ª2015 Elsevier Inc. 35
Histology Sectional and Pathology Scoring
Colon tissues were fixed with 4% paraformaldehyde and embedded in
paraffin, and 5 mm sections were cut and stained with hematoxylin and eosin.
H&E-stained colon tissue sections were blindly scored as described (Jarchum
et al., 2012) based on epithelial degeneration/cell death, edema, and cellular
infiltration, with each parameter scored from 0 to 3.
Statistical Analysis
Results represent means ± SEM. Statistical significance was determined by the
unpaired t test,Mann-Whitney test for n%5, two-wayANOVAtest for timecourse
experiments, and log-rank test for survival curve. Statistical analyses were per-
formedusing PrismGraphPad software v6.0 (* p < 0.05; ** p < 0.01; *** p < 0.001).
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